BCLSI
SVRA icon

Bain Capital Life Sciences Investors’s Savara SVRA Stock Holding History

Bain Capital Life Sciences Investors’s Portfolio SVRA Stock Details SVRA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$96.1M Hold
17,600,621
– – 8.67% 4
2025
Q4 		$106M Hold
17,600,621
– – 8.13% 4
2025
Q3 		$62.8M Hold
17,600,621
– – 4.17% 6
2025
Q2 		$40.1M Hold
17,600,621
– – 5.02% 6
2025
Q1 		$48.8M Buy
17,600,621
+3,035,164
+21% +$8.38M 7.21% 6
2024
Q4 		$44.7M Hold
14,565,457
– – 5.26% 6
2024
Q3 		$61.8M Hold
14,565,457
– – 6.43% 5
2024
Q2 		$58.7M Hold
14,565,457
– – 6.44% 6
2024
Q1 		$72.5M Buy
14,565,457
+332,706
+2% +$1.61M 5.83% 7
2023
Q4 		$66.9M Hold
14,232,751
– – 6.41% 6
2023
Q3 		$53.8M Buy
14,232,751
+2,610,153
+22% +$9.31M 6.02% 6
2023
Q2 		$37.1M Hold
11,622,598
– – 3.82% 7
2023
Q1 		$22.7M Hold
11,622,598
– – 2.83% 12
2022
Q4 		$18M Hold
11,622,598
– – 2.01% 16
2022
Q3 		$18M Hold
11,622,598
– – 2.15% 17
2022
Q2 		$17.7M Hold
11,622,598
– – 2.07% 15
2022
Q1 		$15.2M Hold
11,622,598
– – 1.48% 17
2021
Q4 		$14.4M Hold
11,622,598
– – 1.14% 19
2021
Q3 		$16M Hold
11,622,598
– – 1% 21
2021
Q2 		$19.8M Hold
11,622,598
– – 1.29% 18
2021
Q1 		$24.2M Buy
11,622,598
+6,494,005
+127% +$11.1M 1.37% 15
2020
Q4 		$5.9M Hold
5,128,593
– – 0.37% 21
2020
Q3 		$23M Hold
5,128,593
– – 2.14% 12
2020
Q2 		$23M Hold
5,128,593
– – 2.41% 10
2020
Q1 		$23M Hold
5,128,593
– – 3.89% 7
2019
Q4 		$23M Buy
+5,128,593
New +$6.17M 3.43% 6

Other funds holding SVRA

NMC
NEA Management Company Timonium, Maryland $1.76B AUM 223.33% 1-Year Est. Return
VA
VR Adviser New York $2.68B AUM 422.73% 1-Year Est. Return
DM
Deerfield Management New York $8.48B AUM 99.04% 1-Year Est. Return
TCM
TCG Crossover Management Palo Alto, California $3.5B AUM 1,165.83% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
FLSM
Frazier Life Sciences Management Palo Alto, California $3.89B AUM 201.1% 1-Year Est. Return
PCH
Polar Capital Holdings London, United Kingdom $28.2B AUM 115.26% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
NCM
Nantahala Capital Management New Canaan, Connecticut $2.72B AUM 121.58% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Bain Capital Life Sciences Investors's SVRA Position: Q1 2026 in Review

Bain Capital Life Sciences Investors held its Savara (SVRA) position steady in Q1 2026 at 17,600,621 shares worth $96.1M. The position accounts for 8.67% of the portfolio, ranked #4.

Bain Capital Life Sciences Investors first reported a position in SVRA in Q4 2019 and has held it in 26 quarters since. The position peaked at $106M in Q4 2025. 186 funds tracked by Wall St. Rank hold SVRA as of Q1 2026.

  • Bain Capital Life Sciences Investors held 17,600,621 shares of Savara worth $96.1M as of Q1 2026.
  • Bain Capital Life Sciences Investors left its Savara share count unchanged in Q1 2026.
  • Savara made up 8.67% of Bain Capital Life Sciences Investors's portfolio in Q1 2026, its #4 holding.
  • Bain Capital Life Sciences Investors first reported a position in Savara in Q4 2019 and has held it in 26 quarters since.
  • Bain Capital Life Sciences Investors's Savara position peaked at $106M in Q4 2025.
  • 186 funds tracked by Wall St. Rank held Savara as of Q1 2026.

Based on Bain Capital Life Sciences Investors's 13F filing for Q1 2026, filed 15 May 2026.